Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (2024)

Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (1) https://doi.org/10.1097/ju9.0000000000000040

Journal: JU Open Plus, 2023, №8

Publisher: Ovid Technologies (Wolters Kluwer Health)

Authors: Bilal Chughtai, Naeem Bhojani, Kevin C. Zorn, Dean Elterman

Abstract

ABSTRACT <jats:sec> Purpose: Some men with mild-to-moderate benign prostatic hyperplasia/lower urinary tract symptoms use saw palmetto supplements to proactively manage their symptoms as an alternative to watchful waiting and/or to avoid prescription medication side effects. This study assessed the potency and authenticity of commercially available saw palmetto–based supplements in the United States. </jats:sec> <jats:sec> Materials and Methods: Twenty-eight saw palmetto berry powders, powdered extracts, berry blends, lipid extracts, and multiactive products (lycopene, pumpkin oil, etc) were purchased from major online retailers and retail stores. Total fatty acid content (% weight/weight) and individual fatty acid profile of each product were determined using validated gas chromatography-fatty acid methyl ester methodology and compared with the US Pharmacopeia monograph standards for lipidosterolic extracts of <jats:italic toggle="yes">Serenoa repens. </jats:sec> <jats:sec> Results: Total fatty acid content ranged from 0.796% for a berry powder product to 89.923% for a lipid extract product. None of the berry powders or powdered extracts, 6 of 9 lipid extracts, and 1 multiactive product met criteria for ≥80% total fatty acid content. Only 1 of the 28 products met the US Pharmacopeia criteria for a standardized lipidosterolic extract, defined as total fatty acid content ≥80% and a fatty acid profile indicative of authentic <jats:italic toggle="yes">S. repens based on the ratios of the lauric acid concentration to 9 other individual fatty acid concentrations. </jats:sec> <jats:sec> Conclusions: There is substantial heterogeneity in fatty acid content and profile in saw palmetto supplements. Lipidosterolic extracts of saw palmetto berries standardized to ≥80% fatty acids are most likely to meet established criteria for quality and identity. </jats:sec>

List of references

  1. MacDonald, Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review, BJU Int., № 109, с. 1756
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (2) https://doi.org/10.1111/j.1464-410X.2012.11172.x
  2. Strum, Serenoa repens (saw palmetto) for lower urinary tract symptoms (LUTS): the evidence for efficacy and safety of lipidosterolic extracts. Part II, Uro., № 1, с. 139
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (3) https://doi.org/10.3390/uro1030016
  3. Nickel, Rethinking the role of saw palmetto extract for men with lower urinary tract symptoms in North America, Uro., № 2, с. 137
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (4) https://doi.org/10.3390/uro2030017
  4. Perry, Real-world use of Permixon® in benign prostatic hyperplasia—determining appropriate monotherapy and combination treatment, Adv Ther., № 29, с. 538
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (5) https://doi.org/10.1007/s12325-012-0024-x
  5. Ravenna, Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines, Prostate., № 29, с. 219
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (6) https://doi.org/10.1002/(SICI)1097-0045(199610)29:4<219::AID-PROS3>3.0.CO;2-6
  6. Bayne, The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate, J Urol., № 164, с. 876
  7. Pinthus, Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer, Prostate., № 67, с. 1330
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (7) https://doi.org/10.1002/pros.20609
  8. Roehrborn, Pathology of benign prostatic hyperplasia, Int J Impot Res., № 20, с. S11
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (8) https://doi.org/10.1038/ijir.2008.55
  9. Abe, Isolation and pharmacological characterization of fatty acids from saw palmetto extract, Anal Sci., № 25, с. 553
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (9) https://doi.org/10.2116/analsci.25.553
  10. Petrangeli, Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization, J Cell Physiol., № 219, с. 69
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (10) https://doi.org/10.1002/jcp.21648
  11. Liu, Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach, Anticancer Res., № 30, с. 369
  12. Buonocore, Serenoa repens extracts: in vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia, Arch Ital Urol Androl., № 90, с. 199
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (11) https://doi.org/10.4081/aiua.2018.3.199
  13. Bernichtein, Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia, Prostate., № 75, с. 706
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (12) https://doi.org/10.1002/pros.22953
  14. Latil, Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro, BJU Int., № 110, с. E301
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (13) https://doi.org/10.1111/j.1464-410X.2012.11144.x
  15. de la Taille, Therapeutic approach: the importance of controlling prostatic inflammation, Eur Urol Suppl., № 12, с. 116
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (14) https://doi.org/10.1016/j.eursup.2013.08.003
  16. Raynaud, Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of Permixon®, J Steroid Biochem Mol Biol., № 82, с. 233
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (15) https://doi.org/10.1016/S0960-0760(02)00187-5
  17. Cartwright, Lipid profile and 5-alpha-Reductase inhibition activity of proprietary ultrahigh-pressure supercritical carbon dioxide and hexane saw palmetto extracts, Uro., № 3, с. 27
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (16) https://doi.org/10.3390/uro3010005
  18. Governa, Hypothesis onSerenoa repens(Bartram) small extract inhibition of prostatic 5α-reductase through an in silico approach on 5β-reductase x-ray structure, Peer J., № 4, с. e2698
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (17) https://doi.org/10.7717/peerj.2698
  19. Csikós, Treatment of benign prostatic hyperplasia by natural drugs, Molecules, № 26, с. 7141
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (18) https://doi.org/10.3390/molecules26237141
  20. Mikaelian, Authenticating saw palmetto extract: a new approach, Nutraceutical Business Technol Mag., № 5, с. 24
  21. Lerner, Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management, J Urol., № 206, с. 806
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (19) https://doi.org/10.1097/JU.0000000000002183
  22. Bent, Saw palmetto for benign prostatic hyperplasia, N Engl J Med., № 354, с. 557
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (20) https://doi.org/10.1056/NEJMoa053085
  23. Habib, Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract, Prostate Cancer Prostatic Dis., № 7, с. 195
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (21) https://doi.org/10.1038/sj.pcan.4500746
  24. Perini, Combined use of isotopic fingerprint and metabolomics analysis for the authentication of saw palmetto (Serenoa repens) extracts, Fitoterapia., № 127, с. 15
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (22) https://doi.org/10.1016/j.fitote.2018.04.011
  25. Currier, Herbal medicines, SciMedicine., № 7, с. 40
  26. Gafner, Botanical ingredient forensics: detection of attempts to deceive commonly used analytical methods for authenticating herbal dietary and food ingredients and supplements, J Nat Prod., № 86, с. 460
    Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (23) https://doi.org/10.1021/acs.jnatprod.2c00929

Publications that cite this publication

JU Open Plus: The Train to Seoul

John W. Davis

Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (24) https://doi.org/10.1097/ju9.0000000000000061

2023, JU Open Plus, №9

Crossref citations:0

Find all citations of the publication

About this publication

Publication type Журнальна стаття
Number of citations 1
Number of works in the list of references 26
Journal indexed in Scopus No
Journal indexed in Web of Science No
Variability of Commercial Saw Palmetto–Based Supplements for the Management of Benign Prostatic Hyperplasia/Lower Urina… (2024)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Corie Satterfield

Last Updated:

Views: 5683

Rating: 4.1 / 5 (62 voted)

Reviews: 85% of readers found this page helpful

Author information

Name: Corie Satterfield

Birthday: 1992-08-19

Address: 850 Benjamin Bridge, Dickinsonchester, CO 68572-0542

Phone: +26813599986666

Job: Sales Manager

Hobby: Table tennis, Soapmaking, Flower arranging, amateur radio, Rock climbing, scrapbook, Horseback riding

Introduction: My name is Corie Satterfield, I am a fancy, perfect, spotless, quaint, fantastic, funny, lucky person who loves writing and wants to share my knowledge and understanding with you.